Drugs / Autologous midbrain dopamine neurons
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06422208 | Aug 2024 → Dec 2026 expected | Parkinson disease | Penelope J. Hallett, Ph.D. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous midbrain dopamine neurons | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06422208 ↗ |
| Modality | Cell therapy | “The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells.” NCT06422208 ↗ |
| Route | Other | “will be surgically administered into the putamen, unilaterally, in a single surgical session.” NCT06422208 ↗ |